Efficacy and safety of atorvastatin after pediatric heart transplantation

被引:29
作者
Chin, C [1 ]
Gamberg, P [1 ]
Miller, J [1 ]
Luikart, H [1 ]
Bernstein, D [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA
关键词
D O I
10.1016/S1053-2498(02)00455-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lipid abnormalities are prevalent after pediatric and adult heart transplantation. 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are efficacious and safe and can lower the incidence of graft coronary artery disease after heart transplantation in. adults. Given the high prevalence of lipid abnormalities and the increased recognition of graft coronary disease in children, we retrospectively investigated the efficacy and safety of atorvastatin among pediatric heart transplant recipients. Methods: Thirty-eight patients were started on atorvastatin 48.2 +/- 54.4 months after transplantation. Atorvastatin dosage was 0.2 +/- 0.1 mg/kg per day. No patient had changes in drug dose unless there was evidence for rhabdomyolysis, myositis or an asymptomatic rise in creatine kinase,above normal. Laboratory studies included total cholesterol, triglycerides; high, low and very low-density lipoproteins (HDL, LDL and VLDL, respectively); creatine kinase; creatine; and serum alanine transaminase. Results: Significant declines in total cholesterol (20%), triglyceride (18%) and LDL (26%) were observed after starting atorvastatin therapy. There were no significant changes in HDL or VLDL compared with baseline. There were also no differences in alanine transaminase pre- vs post-atorvastatin therapy. Complications included muscle pain (n = 2) and asymptomatic elevations in creatine kinase (n = 2). Two of these 4 patients developed rhabdomyolysis. Excluding these 4 patients, creatine kinase did not rise compared with baseline. No patient developed alterations in renal function. Conclusions: Use of atorvastatin in pediatric heart transplant recipients is effective in lowering total cholesterol, triglyceride and LDL without altering HDL levels. Complications included rhabdomyolysis, seen in 5%. Baseline and routine screening of creatine kinase should be employed in all pediatric patients undergoing HMG-CoA reductase inhibitor therapy.
引用
收藏
页码:1213 / 1217
页数:5
相关论文
共 18 条
[1]  
ABRAMOWICZ M, 2001, MED LETT DRUGS THER, V43, P43
[2]   HYPERLIPIDEMIA AFTER HEART-TRANSPLANTATION - REPORT OF A 6-YEAR EXPERIENCE, WITH TREATMENT RECOMMENDATIONS [J].
BALLANTYNE, CM ;
RADOVANCEVIC, B ;
FARMER, JA ;
FRAZIER, OH ;
CHANDLER, L ;
PAYTONROSS, C ;
COCANOUGHER, B ;
JONES, PH ;
YOUNG, JB ;
GOTTO, AM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (06) :1315-1321
[3]  
BALLANTYNE CM, 1987, TRANSPL P, V19, P60
[4]   An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor [J].
Black, DM ;
Bakker-Arkema, RG ;
Nawrocki, JW .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (06) :577-584
[5]  
Chin C, 2000, Pediatr Transplant, V4, P193, DOI 10.1034/j.1399-3046.2000.00112.x
[6]  
JOHNSON MR, 1992, J HEART LUNG TRANSPL, V11, pS124
[7]   Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease [J].
Kato, T ;
Tokoro, T ;
Namii, Y ;
Kobayashi, T ;
Hayashi, S ;
Yokoyama, I ;
Morimoto, S ;
Chan, M ;
Giannetti, N ;
Hunt, SA .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (02) :331-333
[8]   Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation [J].
Keogh, A ;
Macdonald, P ;
Kaan, A ;
Aboyoun, C ;
Spratt, P ;
Mundy, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (06) :529-537
[9]  
KEOGH A, 1988, J HEART TRANSPLANT, V7, P171
[10]   EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION [J].
KOBASHIGAWA, JA ;
KATZNELSON, S ;
LAKS, H ;
JOHNSON, JA ;
YEATMAN, L ;
WANG, XM ;
CHIA, D ;
TERASAKI, PI ;
SABAD, A ;
COGERT, GA ;
TROSIAN, K ;
HAMILTON, MA ;
MORIGUCHI, JD ;
KAWATA, N ;
HAGE, A ;
DRINKWATER, DC ;
STEVENSON, LW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) :621-627